Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa

Archives of Ophthalmology

Volumn 121, Issue 9, 2003, Pages 1269-1278

  Wheaton, Dianna H ^a,c   Hoffman, Dennis R ^a,b   Locke, Kirsten G ^a   Watkins, Reginald B ^a   Birch, David G ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c RETINA FOUNDATION OF THE SOUTHWEST   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; CHOLESTEROL; DOCOSAHEXAENOIC ACID; FATTY ACID; FREE RADICAL; LIPOPROTEIN; POLYUNSATURATED FATTY ACID; RETINOL; TRIACYLGLYCEROL; ANTIOXIDANT; LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BIOSAFETY; BLEEDING; BLEEDING TIME; BLOOD SAMPLING; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ERUCTATION; GASTROINTESTINAL SYMPTOM; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; OXIDATION; OXIDATIVE STRESS; PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS PIGMENTOSA; SIDE EFFECT; SUPPLEMENTATION; THROMBOCYTE AGGREGATION; VITAMIN BLOOD LEVEL; X CHROMOSOME LINKAGE; BIOAVAILABILITY; BLOOD; DIET SUPPLEMENTATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PRESCHOOL CHILD; SAFETY; X CHROMOSOME LINKED DISORDER;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; FATTY ACIDS; GENETIC DISEASES, X-LINKED; HUMANS; LIPOPROTEINS; MALE; PLATELET AGGREGATION; RETINITIS PIGMENTOSA; SAFETY; TRIGLYCERIDES; VITAMIN A; VITAMIN E;

EID: 0141499056     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.9.1269     Document Type: Article

References (58)

1. McColl AJ, Converse CA. Lipid studies in retinitis pigmentosa. Prog Lipid Res. 1995;34:1-16.
2. Hoffman DR. Fatty acids and visual dysfunction. In: Chow CK, ed. Fatty Acids in Foods and Their Health Implications. New York, NY: Marcel Dekker Inc; 2000:817-842.
3. Hoffman DR, Birch DG. Docosahexaenoic acid in red blood cells of patients with X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1995;36:1009-1018.
4. Gong J, Rosner B, Rees DG, Berson EL, Weigel-DiFranco CA, Schaefer EJ. Plasma docosahexaenoic acid levels in various genetic forms of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1992;33:2596-2602.
5. Schaefer EJ, Robins SJ, Patton GM, et al. Red blood cell membrane phosphatidylethanolamine fatty acid content in various forms of retinitis pigmentosa. J Lipid Res. 1995;36:1427-1433.
6. Hoffman DR, Wheaton DH, Locke K, Birch DG. Rod ERG function and erythrocyte docosahexaenoic (DHA) in X-linked retinitis pigmentosa (XLRP) [abstract]. Invest Ophthalmol Vis Sci. 1997;38:S797.
7. Hoffman DR, Wheaton DH, Locke K, Birch DG. Docosahexaenoic acid (DHA) in red blood cells and electroretinographic (ERG) function in carrier heterozygotes of X-linked retinitis pigmentosa (XLRP) [abstract]. Invest Ophthalmol Vis Sci. 1998;39:S725.
8. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr. 1992;120(pt 2):S129-S138.
9. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res. 1983;22:79-131.
10. Salem NJ, Litman B, Kim H-Y, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001;36:945-959.
11. Deese AJ, Dratz EA, Dahlquist FW, Paddy MR. Interaction of rhodopsin with two unsaturated phosphatidylcholines. Biochemistry. 1981;20:6420-6427.
12. 3H-docosahexaenoyl] phosphatidate to rhodopsin during in vivo labeling of frog retinal rod outer segments. Neurochem Res. 2000;25:695-703.
13. Niu SL, Mitchell DC, Litman BJ. Optimization of receptor-G protein coupling by bilayer lipid composition, II. J Biol Chem. 2001;276:42807-42811.
14. Mitchell DC, Niu SL, Litman BJ. Optimization of receptor-G protein coupling by bilayer lipid composition, I. J Biol Chem. 2001;276:42801-42806.
15. Litman BJ, Mitchell DC. A role for phospholipid polyunsaturation in modulating membrane protein function. Lipids. 1996;31(suppl):S193-S197.
16. Fishman GA, Farber MD, Derlacki DJ. X-linked retinitis pigmentosa: profile of clinical findings. Arch Ophthalmol. 1988;106:369-375.
17. Birch DG, Anderson JL, Birch EE. Early abnormalities of rod function in children with X-linked retinitis pigmentosa. Clin Vision Sci. 1993;8:329-335.
18. Birch DG, Anderson JL, Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy. Ophthalmology. 1999;106:258-268.
19. Hoffman DR, Wheaton DH, Locke KG, Fish GE, Birch DG. Four-year outcomes from a randomized clinical trial of docosahexaenoic acid (DHA) supplementation in X-linked retinitis pigmentosa (XLRP) [abstract]. Invest Ophthalmol Vis Sci. 2003;44:E-abstract 4851. Available at: http://abstracts.iovs.org/cgi/content/abstract/44/5/4851.
20. Anderson RE, Maude MB, Alvarez RA, Acland G, Aguirre GD. A hypothesis to explain the reduced blood levels of docosahexaenoic acid in inherited retinal degenerations caused by mutations in genes encoding retina-specific proteins. Lipids. 1999;34(suppl):S235-S237.
21. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr. 1997;65(suppl):1687S-1698S.
22. Wheaton DH, Daiger SP, Birch DG. The Southwest Eye Registry: distribution of disease types and mutations. In: Anderson RE, LaVail MM, Hollyfield JG, eds. New Insights Into Retinal Degenerative Diseases. New York, NY: Kluwer-Plenum; 2001:339-345.
23. Kyle DJ, Arterburn LM. Single cell oil sources of docosahexaenoic acid: clinical studies. World Rev Nutr Diet. 1998;83:116-131.
24. Hoffman DR, DeMar JC, Heird WC, Birch DG, Anderson RE. Impaired synthesis of DHA in patients with X-linked retinitis pigmentosa. J Lipid Res. 2001;42:1395-1401.
25. Hoffman DR, Uauy R, Birch DG. Metabolism of omega-3 fatty acids in patients with autosomal dominant retinitis pigmentosa. Exp Eye Res. 1995;60:279-289.
26. Bui MH. Simple determination of retinol, α-tocopherol and carotenoids (lutein, all-trans-lycopene, α-and β-carotenes) in human plasma by isocratic liquid chromatography. J Chromatogr B Biomed Appl. 1994;654:129-133.
27. Whitehead TP, Thorpe GHG, Maxwell SRJ. Enhanced chemiluminescent assay for antioxidant capacity in biological fluids. Anal Chim Acta. 1992;266:265-277.
28. Williams JC, Forster LA, Tull SP, Wong M, Bevan RJ, Ferns GAA. Dietary vitamin E supplementation inhibits thrombin-induced platelet aggregation, but not monocyte adhesiveness, in patients with hypercholesterolaemia. Int J Exp Pathol. 1997;78:259-266.
29. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
30. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121:641-647.
31. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. NIH consensus conference: triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269:505-510.
32. Parkinson AJ, Cruz AL, Heyward WL, et al. Elevated concentrations of plasma ω-3 polyunsaturated fatty acids among Alaskan Eskimos. Am J Clin Nutr. 1994;59:384-388.
33. Innis SM, Hansen JW. Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults. Am J Clin Nutr. 1996;64:159-167.
34. Nelson GJ, Schmidt PS, Bartolini GL, Kelley DS, Kyle DJ. The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids. 1997;32:1129-1136.
35. Okuyama H, Kobayashi T, Watanabe S. Dietary fatty acids-the N-6/N-3 balance and chronic elderly diseases. Prog Lipid Res. 1996;35:409-457.
36. Lands WEM, Morris A, Libelt B. Quantitative effects of dietary polyunsaturated fats on the composition of fatty acids in rat tissues. Lipids. 1990;25:505-516.
37. Hu FB. The balance between ω-6 and ω-3 fatty acids and the risk of coronary heart disease. Nutrition. 2001;17:741-742.
38. Okuyama H. Recommended LNA/LA ratio for the prevention of chronic elderly diseases [abstract]. Paper presented at: 88th American Oil Chemist's Society Annual Meeting and Expo; May 12, 1997; Seattle, Wash.
39. Koletzko B, Agostoni C, Carlson SE, et al. Long chain polyunsaturated fatty acids (LC-PUFA) and perinatal development. Acta Paediatr. 2001;90:460-464.
40. Kris-Etherton PM, Shaffer Taylor D, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000;71(suppl):179S-188S.
41. Middaugh JP. Cardiovascular disease among Alaskan Natives, 1980-89. Am J Public Health. 1990;80:282-285.
42. Davidson M, Bulkow LR, Gellin BG. Cardiac mortality in Alaska's indigenous and non-Native residents. Int J Epidemiol. 1993;22:62-67.
43. Suh M, Wierzbicvi AA, Lien EL, Clandinin MT. Dietary 20:4n-6 and 22:6n-3 modulates the profile of long- and very-long-chain fatty acids, rhodopsin content, and kinetics in developing photoreceptor cells. Pediatr Res. 2000;48:524-530.
44. Organisciak DT, Darrow RM, Jiang YL, Blanks JC. Retinal light damage in rats with altered levels of rod outer segment docosahexaenoate. Invest Ophthalmol Vis Sci. 1996;37:2243-2257.
45. Penn JS, Anderson RE. Effect of light history on rod outer-segment membrane composition in the rat. Exp Eye Res. 1987;44:767-768.
46. Budowski P. The omega-3 fatty acid peroxidation paradox. Redox Rep. 1996;2:75-77.
47. Rotstein NP, Aveldano MI, Barrantes FJ, Roccamo AM, Politi LE. Apoptosis of retinal photoreceptors during development in vitro: protective effect of docosahexaenoic acid. J Neurochem. 1997;69:504-513.
48. Reinboth JJ, Clausen M, Reme CE. Light elicits the release of docosahexaenoic acid from membrane phospholipids in the rat retina in vitro. Exp Eye Res. 1996;63:277-284.
49. Wang J-Y, Saito M. Dietary supplementation of N-3 fatty acids and hydroperoxide levels in rat retinas. Free Radic Res. 2001;35:367-375.
50. Koutz CA, Wiegand RD, Rapp LM, Anderson RE. Effect of dietary fat on the response of the rat retina to chronic and acute light stress. Exp Eye Res. 1995;60:307-316.
51. Jensen RG. Lipids in human milk. Lipids. 1999;34:1243-1271.
52. Birch EE, Hoffman DR, Uauy R, Birch DG, Prestidge C. Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr Res. 1998;44:201-209.
53. Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42:174-181.
54. Hoffman DR, Birch EB, Birch DG, et al. Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development. J Pediatr Gastroenterol Nutr. 2000;31:540-543.
55. Simopoulos AP, Leaf A, Salem NJ. Conference report: workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. J Am Coll Nutr. 1999;18:487-489.
56. Burns CP, Halabi S, Clamon GH, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia. Clin Cancer Res. 1999;5:3942-3947.
57. Stone NJ. The Gruppo Italiano per lo Studio della Sopravvivenze nell'Infarto Miocardio (GISSI)-Prevenzione Trial on fish oil and vitamin E supplementation in myocardial infarction survivors. Curr Cardiol Rep. 2000;2:445-451.
58. Volker D, Fitzgerald P, Major G, Garg M. Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol. 2000;27:2343-2346.